Assertio Announces Partnership with the Lennox-Gastaut Syndrome (LGS) Foundation
17 janv. 2023 09h00 HE
|
Assertio Holdings, Inc.
SYMPAZAN® (clobazam) oral film from Assertio is used for the adjunctive treatment of seizures associated with LGS in patients two years of age and olderOral film delivery from SYMPAZAN® delivers...
Assertio Holdings, Inc. Announces FDA Orange Book Listing for New Sympazan® Oral Film Patent
09 janv. 2023 16h15 HE
|
Assertio Holdings, Inc.
LAKE FOREST, Ill., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a specialty pharmaceutical company offering differentiated products to...
Assertio Reports Third Quarter 2022 Financial Results
08 nov. 2022 16h01 HE
|
Assertio Holdings, Inc.
Net Product Sales Increase 32% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases 36%Increases Guidance for Net Product Sales and Adjusted EBITDADebt Refinancing Extends Maturity, Reduces Cost and...
Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.
27 oct. 2022 09h00 HE
|
Assertio Holdings, Inc.
Trailing 12 Month Revenues of Sympazan Were $9.5 MillionAssertio Paid $9.0 Million Upfront, Additional $6.0 Million upon Patent Allowance LAKE FOREST, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) --...